We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pharmacogenetics of Cannabinoid Response

This study is ongoing, but not recruiting participants.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00678730
First Posted: May 15, 2008
Last Update Posted: June 23, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Deepak C. D'Souza, Yale University
May 13, 2008
May 15, 2008
June 23, 2017
July 2007
July 2018   (Final data collection date for primary outcome measure)
Behavioral Measures [ Time Frame: Baseline, +15, +25, +60, +300 ]
PANSS: Psychotic symptoms will be measured using the Positive and Negative Syndrome Scale (PANSS). Rey Auditory Verbal Learning Test (AVLT): a 15 word list learning task of verbal memory and hippocampal function that has 6 alternate versions. [ Time Frame: Baseline, +15, +25(RAVLT only), +60, +300 ]
Complete list of historical versions of study NCT00678730 on ClinicalTrials.gov Archive Site
Not Provided
CADSS:scale that measures perceptual alterations.Visual Analog Scale: a 16-item feeling state scale associated with cannabis.CANTAB: a computerized cognitive test battery is used to measure attention and memory. [ Time Frame: Baseline, +15, +35 (CANTAB only), +60, +300 ]
Not Provided
Not Provided
 
Pharmacogenetics of Cannabinoid Response
Pharmacogenetics of Cannabinoid Response
This study attempts to examine genetic influences on the effects of tetrahydrocannabinol (Δ9-THC), the active ingredient of marijuana, cannabis, "ganja", or "pot".
Not Provided
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
COMT Gene Polymorphism
Drug: delta 9 tetrahydrocannabinol
0.05 mg/kg of THC dissolved in ethanol intravenously over 20 minutes
Other Names:
  • Marijuana
  • cannabis
  • Active Comparator: 1
    • Very low dose (0.005 mg/kg = 0.35 mg in a 70kg individual) THC, dissolved in ethanol. This dose is roughly equivalent to smoking 1/10th of a marijuana cigarette, or "joint".
    • Low dose (0.025 mg/kg = 1.75 mg in a 70kg individual) THC, dissolved in ethanol. This dose is roughly equivalent to smoking 1/2 of a marijuana cigarette, or "joint".
    • Medium dose (0.05 mg/kg = 3.5 mg in a 70 kg individual) THC, dissolved in ethanol. This dose is roughly equivalent to smoking 1 marijuana cigarette, or "joint".
    Intervention: Drug: delta 9 tetrahydrocannabinol
  • Placebo Comparator: 2
    small amount of ethanol, (quarter teaspoon), with no THC
    Intervention: Drug: delta 9 tetrahydrocannabinol
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
162
July 2018
July 2018   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • 18 and 55 years (extremes included) on the day of the first dosing.

Exclusion Criteria:

  • Cannabis naïve individuals.
Sexes Eligible for Study: All
18 Years to 55 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00678730
0706002754
Not Provided
Not Provided
Not Provided
Deepak C. D'Souza, Yale University
Yale University
National Institute on Drug Abuse (NIDA)
Principal Investigator: Deepak D'Souza, M.D. Yale University
Yale University
June 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP